Surveillance Protocols for Survivors at Risk for Lymphedema

Purpose of Review Breast cancer treatments introduce risk for developing lymphedema. There are identifiable tissue and sensory changes that are associated with the onset of breast cancer-related lymphedema (BCRL) that can enhance early identification and treatment of the condition. Therefore, there exists an unprecedented opportunity to employ surveillance protocols to monitor for the earliest signs and symptoms of the condition. Recent Findings Standardized methods for prospective surveillance have been investigated and show effectiveness in promoting early identification and early management of BCRL. Furthermore, there is emerging evidence that this approach can support broad assessment of physical function for individuals with breast cancer, improving quality of life and potentially reducing cost associated with treatment-related morbidity. Summary This article provides an overview of the prospective surveillance model (PSM), an optimal framework for early identification of BCRL in individuals at risk, shares implementation strategies across two different cultures, and suggests future direction for research and clinical practice to enhance implementation.